Indiana Biosciences Research Institute
Michele Sawyer, CPA, currently serves as Executive Vice President and Chief Financial Officer at the Indiana Biosciences Research Institute since September 2022, where responsibilities include financial leadership, oversight of the endowment, and advancement initiatives. Prior to this role, Michele held significant positions at Elanco, including Executive Director Finance and General Auditor, where leadership was provided during the company's IPO and the management of a large auditing team. Michele's extensive background at Eli Lilly and Company encompassed roles such as Director Corporate Financial Planning and Controller of the R&D Portfolio, delivering strategic financial insights and managing substantial budgets. Michele holds a BS in Business with concentrations in Accounting and International Business from Indiana University - Kelley School of Business and additional education from the University of Limburg in the Netherlands.
This person is not in any teams
Indiana Biosciences Research Institute
The Indiana Biosciences Research Institute (IBRI) is a leading translational research institute that advances academic and industry science through collaboration to improve patient health outcomes. Our institute was founded on the mission to improve the health of Hoosiers who were living with diabetes. While we are still on the ambitious path envisioned by our founders, we are taking what we’ve learned, building new capabilities and applying it to other diseases, such as Alzheimer’s disease and cancer. We are positioned with a unique interface to academia, industry and government research. This gives us the ability to explore opportunities with a broad spectrum of innovators and collaboration models. It allows us to extend the reach of all researchers and create scientific possibilities that otherwise would not exist. It also helps us attract and retain researchers to strengthen the life sciences community and be the foundation of continual economic growth for the state. Science is advancing at a rapid pace. Unprecedented access to novel genetic and genomic analyses of disease tissues along with human-derived models for preclinical experimental work have opened new ways to study disease and pursue novel interventions. These approaches have led to a better molecular understanding of disease and patient heterogeneity, in addition to new therapeutic hypotheses to explore. It is ultimately our goal to return these findings to patients in the form of novel therapies and diagnostics that improve disease outcomes. The four foundational areas of scientific focus at the IBRI – diseases, systems, pathways; enabling technologies; integrated data sciences; and molecular innovation – will provide us the core talent and capability to pursue translational science in this new patient-centric framework. Our mission is to become the leading applied research institute in the discovery and development of innovative solutions to improve human health.